Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Fluorodopa PET scanning in Parkinson’s disease]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022	NIHR Health Technology Assessment programme	Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Corneal collagen crosslinking with riboflavin in keratoconus]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022	NIHR Health Services and Delivery Research programme	Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Antiangiogenic drugs in refractory age-related macular degeneration]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022	Andalusian Health Technology Assessment Area (AETSA)	[Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2021	Scottish Medicines Consortium (SMC)	Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Crizanlizumab for preventing sickle cell crises in sickle cell disease. NICE technology appraisal guidance 743
2021	Scottish Medicines Consortium (SMC)	Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021	Health Technology Wales (HTW)	Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021	NIHR Health Technology Assessment programme	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
2021	Belgian Health Care Knowledge Centre (KCE)	Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021	National Institute for Health and Care Excellence (NICE)	NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways: a systematic review
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	WorkSafeBC	Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021	Center for Drug Evaluation (CDE)	Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021	WorkSafeBC	Acupuncture or massage therapy as treatment for occipital neuralgia
2021	National Institute for Health and Care Excellence (NICE)	Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Center for Drug Evaluation (CDE)	Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021	Health Technology Wales (HTW)	Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021	NIHR Health Technology Assessment programme	Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751
2021	Norwegian Institute of Public Health (NIPH)	[Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality for TAVI]
2021	National Institute for Health and Care Excellence (NICE)	Belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE technology appraisal guidance 752
2021	Andalusian Health Technology Assessment Area (AETSA)	[18F-FDG in myocardial viability for revascularization]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021	National Institute for Health and Care Excellence (NICE)	Cenobamate for treating focal onset seizures in epilepsy. NICE technology appraisal guidance 753
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021	National Institute for Health and Care Excellence (NICE)	Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome. NICE technology appraisal guidance 754
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2021	National Institute for Health and Care Excellence (NICE)	Risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 755
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer; does the use of fusion biopsy lead to better treatment results compared to the use of conventional diagnostic procedures?]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pemigatinib (cholangiocarcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 756
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Palliative care screening tools
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pain in endometriosis: do other procedures instead of painkillers also help?]
2021	HTA South	[Circadian rhythm lighting in psychiatry, care of the elderly and dementia, and rehabilitation]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021	Health Information and Quality Authority (HIQA)	Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021	Andalusian Health Technology Assessment Area (AETSA)	[Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Multiple sclerosis: does the use of mHealth solutions (e.g. apps) lead to better results in the self-management of those affected?]
2021	NIHR Health Services and Delivery Research programme	Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021	NIHR Health Technology Assessment programme	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: thrombotic adverse events with adenovirus vaccines
2021	Andalusian Health Technology Assessment Area (AETSA)	[High intensity focused ultrasound (HIFU) in organ-confined prostate tumors]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	NIHR Health Technology Assessment programme	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Process and evaluation of digital health applications in the context of "symptom-checkers"]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabotegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	Norwegian Institute of Public Health (NIPH)	[Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	National strategies and programmes for preventing and managing non-communicable diseases in selected countries
2021	Malaysian Health Technology Assessment (MaHTAS)	Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021	Norwegian Institute of Public Health (NIPH)	[Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Tracheostomy or endotracheal tubes and subglottic suctioning